Haleon PLC Outcome of audit tender (1556P)
07 February 2023 - 10:50PM
UK Regulatory
TIDMHLN
RNS Number : 1556P
Haleon PLC
07 February 2023
Haleon plc concludes tender for statutory audit
7 February 2023: In its prospectus published June 2022, Haleon
plc (the "Company") (LSE/NYSE: HLN) advised that it expected to
conduct an audit tender process for the audit of the Company's
financial statements for the year ending 31 December 2023, which
would be subject to shareholder approval at the Company's 2023
Annual General Meeting (AGM).
Following the conclusion of a competitive tender process and
recommendation from the Company's Audit and Risk Committee, the
Board has approved the proposed appointment of KPMG LLP as its
statutory auditor following completion of the audit of its accounts
for the year ending 31 December 2022. This appointment will be
recommended to shareholders for approval at the 2023 AGM.
The Company would like to thank Deloitte LLP for their
significant contribution during their time as the Company's
auditors, including their work supporting the demerger and listing
of Haleon as an independent consumer health company. Subject to
shareholder approval at the 2023 AGM, we look forward to working
with KPMG LLP.
Ends
Contacts
Media Zoë Bird +44 7736 746167
Investors Sonya Ghobrial +44 7392 784784
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPSSWSUWEDSEFE
(END) Dow Jones Newswires
February 07, 2023 06:50 ET (11:50 GMT)
Haleon (LSE:HLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Haleon (LSE:HLN)
Historical Stock Chart
From Apr 2023 to Apr 2024